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DIALYSIS – TRANSPLANTATION
Activation of hepatocyte growth factor/activin A/follistatin
system during hemodialysis: Role of heparin
JACEK BORAWSKI, BEATA NAUMNIK, and MICHAL MYS´LIWIEC
Department of Nephrology and Internal Medicine, Medical University, Bialystok, Poland
Activation of hepatocyte growth factor/activin A/follistatin sys-
tem during hemodialysis: Role of heparin.
Background. Hepatocyte growth factor (HGF), activin A,
and follistatin compose an organotrophic system that may be
modulated by heparin. We prospectively studied the effects
of unfractionated heparin (UFH) versus low-molecular-weight
heparin (LMWH) enoxaparin-anticoagulated hemodialysis on
plasma levels of the cytokines.
Methods. The factors were measured by immunoassays in
25 chronic hemodialysis patients at the start and at 10 and
180 minutes of the hemodialysis procedure anticoagulated with
bolus enoxaparin. Then, the patients were randomized to either
receive a bolus and infusion of UFH or to continue LMWH, and
were reexamined after 12 weeks.
Results. Predialysis HGF and follistatin were increased (both
P < 0.0001), while activin A was normal in hemodialysis pa-
tients. Baseline HGF directly correlated with activin A in
hemodialysis subjects (P = 0.004). In healthy controls, it was
positively associated with follistatin (P = 0.001). Both HGF
and activin A were markedly increased at each interval of
enoxaparin-anticoagulated hemodialysis, and follistatin was
increased at 10 minutes (all P < 0.0001). The early increments
in HGF and follistatin directly depended on the dose of enoxa-
parin (both P < 0.030). Remarkably, the rise in activin A was
inversely associated with the predialysis level of the cytokine
(P < 0.0001). The actions of UFH resembled those of LMWH,
although the releasing effects on the growth factors were not
dose-dependent. The switch from LMWH to UFH resulted in
a significant increase in over-dialysis HGF, a fall in follistatin,
and no change in activin A.
Conclusion. HGF/activin A/follistatin system is activated and
disturbed in chronic hemodialysis patients, including deple-
tion of tissue stores of activin A. Type and dose of heparin
used during hemodialysis procedures profoundly influence this
pleiotropic system, and may thus modulate vital body functions
and course of critical diseases.
Hepatocyte growth factor (HGF) is an intrinsic repair
factor with morpho-, mito-, and motogenetic as well as
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antiapoptotic effects on almost every cell of the body
[1, 2]. The expression of HGF in mesenchymal cells and
its c-Met receptor in epithelial cells, including vascular
endothelium and erythroid progenitors, is activated by
the local tissue damage and, interestingly, by the injury
to distant organs. Then, the released cytokine acts in a
complex auto-, para-, and, remarkably, endocrine- and
concentration-dependent manner [1, 2]. Recent experi-
mental studies [3, 4] showed that some of the regenera-
tive effects of HGF in the kidney and lung were strongly
inhibited by activin A, a pluripotent cytokine of the trans-
forming growth factor-b (TGF-b) superfamily [5–9]. Fur-
thermore, follistatin, a principal antagonist of activin A
[5–9], reversed the inhibitory effects of activin A on
the HGF-induced renal tubulogenesis [3]. These studies
indicate that HGF, activin A, and follistatin compose an
organotrophic system [3, 4].
Blood HGF levels in patients undergoing maintenance
hemodialysis are several-fold higher than in healthy sub-
jects [10–13]. They are directly predictive of incident
cardiovascular mortality [12], severity of carotid arte-
riosclerosis [12] and left ventricular hypertrophy [14],
prevalence of cardiovascular disease and viral hepati-
tis [15], closely associated with activated inflammatory
[12, 15], antioxidant [13] and liver-reparative responses
[13, 16], and with less anemia [12, 15]. The increase in
HGF in chronic hemodialysis patients is thus regarded as
an important part of the reparative reaction against the
most common disorders. Studies of activin A and follis-
tatin in this specific population are scarce; only low activ-
ity and normal blood concentrations of activin A [17] and
increased follistatin levels [18] were separately reported
so far.
Circulating HGF levels strikingly increase during
hemodialysis sessions, largely [10, 11] but not exclusively
[11] due to heparin administered as a blood anticoagu-
lant. The mechanism may include displacement of HGF
from cell-surface and extracellular matrix proteoglycans
[19], prolonged lifetime of the circulating HGF/heparin
complexes [20, 21], and an enhanced production of the
cytokine [22, 23]. Recently, heparin was also reported
to remarkably increase blood activin A and follistatin
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levels in patients undergoing cardiovascular procedures,
likely by similar mechanisms [24]. It is thus conceiv-
able that heparin is an under-appreciated modulator of
the HGF/activin A/follistatin system. These pleiotropic
effects of heparin may be of particular importance in
patients undergoing maintenance hemodialysis.
We aimed to determine, for the first time, the relations
between plasma levels of HGF, activin A, and fol-
listatin in chronic hemodialysis patients and healthy
subjects, the over-dialysis profiles of the growth fac-
tors during procedures employing low-molecular-weight
heparin (LMWH) enoxaparin, and to compare the
effects of unfractionated heparin (UFH)- and LMWH-
anticoagulated hemodialysis treatments on plasma
HGF/activin A/follistatin system in a prospective con-
trolled study.
METHODS
Patients
We enrolled 25 patients (15 men, 10 women; mean
age, 59.3 ± 13.3 years) who had been undergoing main-
tenance hemodialysis for a median period of 40.4 months
(range 2.0 to 162 months). All the participants had
been anticoagulated with LMWH enoxaparin (Clexane,
Bellon Rhoˆne-Poulenc Rorer, Montrouge, France) dur-
ing hemodialysis for a minimum of 2 months prior to
the study. Primary renal diseases were chronic glomeru-
lonephritis (N = 8), interstitial nephritis (N = 6), poly-
cystic kidney disease (N = 3), hypertensive nephropathy
(N = 1), secondary amyloidosis (N = 1), acute renal fail-
ure (N = 1), and unknown (N = 5). Exclusion criteria
were severe liver disease, malignancy, diabetes, human
immunodeficiency virus (HIV) infection, treatment with
immunosuppressive, contraceptive, lipid-lowering, an-
tiplatelet or nonsteroidal anti-inflammatory drugs, and
any recent acute inflammatory or infectious diseases. The
patients were dialyzed for 4 to 5 hours 3 times weekly
using the double-needle technique, native arteriove-
nous fistulas, standard bicarbonate buffer, low-flux mod-
ified cellulose dialyzers, and machines with ultrafiltration
controllers.
Before each hemodialysis session, the extracorporeal
circuit was rinsed with 1000 mL of 0.9% saline containing
2.0 IU/mL of UFH (Heparin; Biochemie, Kundl, Austria).
Then, LMWH enoxaparin was administered as a single
bolus of 40 mg (20 to 60 mg) via the first-access needle.
The effective dose of enoxaparin was 0.68 ± 0.20 mg/kg
(1 mg = 100 IU of antifactor Xa activity). It was estab-
lished on the basis of the following clinical guidelines: no
visible fibrin clots in the arterial and venous bubble traps
during hemodialysis, no clotted filters after hemodialy-
sis, and no bleeding from the fistula puncture sites after
compression [25, 26].
Eighteen age- and gender-matched healthy volunteers
served as controls for determination of plasma HGF,
activin A, and follistatin levels.
Study protocol
Plasma HGF, activin A, and follistatin levels in
25 patients anticoagulated with enoxaparin were mea-
sured predialysis (T0) and at 10 minutes (T10) and
180 minutes (T180) after the beginning of hemodialy-
sis. The subjects were next randomized either to con-
tinue enoxaparin (N = 13) or to receive UFH (N = 12).
The study was designed to keep the heparin doses, other
hemodialysis prescriptions and pharmacologic treatment
stable during the follow-up. The study protocol was ap-
proved by the Clinical Research and Ethics Committee
of the Medical University of Bialystok, and all patients
and controls gave their informed consent.
UFH was injected as a bolus of 2500 IU (1500 to
3500 IU) (42.1 ± 9.2 IU/kg) into the arterial line just prior
to the start of hemodialysis, and followed by a continuous
infusion of 3750 IU (2500 to 4000 IU) (57.8 ± 12.4 IU/kg)
via a syringe pump. The total dose of UFH per hemodial-
ysis was 6333 ± 1115 IU (99.9 ± 18.9 IU/kg). The infusion
was started just after the bolus, and stopped 1 hour before
the scheduled end of hemodialysis. The UFH dosage had
been individually titrated on the basis of whole blood
activated partial thromboplastin time (WBAPTT) and
established during the first three sessions after random-
ization. The goal was to attain an approximately twofold
prolongation of WBAPTT at both 30 and 120 minutes of
hemodialysis compared with baseline.
Twenty-three patients were reexamined after a
3-month interval. In the 12 patients who had been ran-
domized to UFH, the over-dialysis plasma HGF, activin
A, and follistatin levels were compared to those obtained
when they were anticoagulated with enoxaparin. Eleven
out of the 13 subjects maintained on hemodialysis treat-
ment with enoxaparin completed the study. Two patients
died out-hospital during the follow-up.
Laboratory procedures
Fasting blood was drawn into ethylenediaminetetraac-
etate (EDTA)-coated vacutainers during a midweek
morning hemodialysis: at T0 from the access (before hep-
arinization), and at T10 and T180 from the predialyzer port
after slowing the blood flow to 100 mL/min for 1 minute.
In healthy controls, fasting morning blood was obtained
without stasis from the antecubital vein punctured with
a 19-gauge needle. Plasma was prepared by centrifuga-
tion at 3000g for 20 minutes at room temperature within
30 minutes of collection, aliquoted, and stored at −40◦C
until assays.
Plasma HGF, activin A, and follistatin levels
were determined using solid-phase enzyme-linked
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immunosorbent assay (ELISA) kits purchased from
R&D Systems, Inc., Minneapolis, MN, USA (Quan-
tikine; cat. no. DHG00, DFN00, and DAC00, re-
spectively). The assays quantify human-specific factors;
their mean minimum detectable levels are 0.04 ng/mL,
2.3 pg/mL, and 29 pg/mL, respectively. The diluent
provided with the activin A kit dissociates the activin
A/follistatin complex in the biologic samples; the assay is
thus capable of quantifying total activin A. The follistatin
assay detects the 288, 300, and 315 amino acid polypep-
tides. All the measurements were performed in dupli-
cate using a 400 SFC photometer (SLT-Labinstruments,
Gro¨ding/Salzburg, Austria) and calibrated using pro-
vided recombinant human reference samples and stan-
dards. For calculations of the results, a computer and
a curve-fitting program were used. The within- and
between-assay coefficients of variations were <8%. The
T180 values were corrected for hemoconcentration ac-
cording to plasma protein levels. WBAPTT was measured
using an automated coagulation system and reagents
from BioMe´rieux (Marcy-l’Etoile, France).
Statistical analysis
Shapiro-Wilk W test of normality was used for data
distribution analysis. The normally distributed data
were presented as mean ± 1 SD, and the skewed data
as median (full range). Intergroup comparisons were
performed with nonparametric Mann-Whitney U test,
Kruskal-Wallis analysis of variance (ANOVA) by ranks
and median test, and with chi-squared analysis, when
appropriate. Intragroup comparisons were performed
with nonparametric Friedman ANOVA by ranks and
Wilcoxon tests. Bivariate correlations between continu-
ous variables were assessed using Spearman regression;
those between dichotomous and continuous factors by
quasi-Newton logistic analysis. All statistical tests were
two-sided, and P < 0.05 was considered significant. Anal-
yses were performed with Statistica software (version 6.0,
StatSoft, Tulsa, OK, USA).
RESULTS
HGF/activin A/follistatin in hemodialysis patients
and healthy subjects
Predialysis plasma HGF and follistatin levels in
hemodialysis patients were markedly higher than in
healthy controls (Table 1). Plasma activin A did not dif-
fer between the groups. In the patients, baseline HGF
directly correlated with activin A (r = 0.549, P = 0.004)
(Fig. 1A); in the controls, HGF was associated with fol-
listatin (r = 0.699, P = 0.001) (Fig. 1B). Other relations
between the markers were non-significant in either group
(all P > 0.168). They were also not associated with ei-
ther gender (all P > 0.473) or age (all P > 0.246). In the
Table 1. Plasma hepatocyte growth factor (HGF), activin A, and
follistatin in patients undergoing enoxaparin-anticoagulated
hemodialysis and in healthy subjects
Hemodialysis Healthy
patients subjects P value
HGF ng/mL 1.84 (0.66–6.20) 0.61 ± 0.17 <0.0001
Activin A pg/mL 143 ± 81.7 111 ± 67.1 0.242
Follistatin pg/mL 3285 ± 1070 1323 ± 403 <0.0001
Blood samples were obtained at the onset of a morning midweek hemodialysis
session in the patients (before heparinization), and in a fasting morning state
in the controls. Normally and not normally distributed data are presented as
mean ± 1 SD and median (range). Two-tailed P by nonparametric Mann-Whitney
U test between the groups.
patients, no significant effects of dialysis vintage (all
P > 0.098) or cause of renal failure (all P > 0.185) on
the markers were found.
HGF/activin A/follistatin during LMWH hemodialysis
Plasma HGF levels significantly changed over enoxa-
parin HD (v 2 ANOVA = 50.0, P< 0.0001) (Fig. 2A).
They increased by a mean of 1631% to 28.7 ng/mL (15.3 to
154 ng/mL) at T10, and by a median of 377% to 8.21 ng/mL
(2.73 to 98.3 ng/mL) at T180 compared with T0 (both P <
0.0001). HGF levels were lower at T180 than at T10 (P <
0.0001).
Plasma activin A levels followed the same pattern
(v 2 ANOVA = 41.2, P< 0.0001) (Fig. 2B). At T10, they
increased by a median of 139% to 357 ± 128 pg/mL. At
T180, activin A levels were 203 ± 67.4 pg/mL, lower than
at T10 (P < 0.0001), but still elevated by a median of 36%
compared with the T0 values (all P < 0.0001).
Plasma follistatin levels also significantly changed over
hemodialysis (v 2 ANOVA = 39.1, P < 0.0001) (Fig. 2C).
At T10, they increased by a median of 53% to 5054 ±
1733 pg/mL (P < 0.0001); at T180, follistatin concentra-
tions were 3211 ± 853 pg/mL and not different from those
at T0 (P = 0.536).
The percentage increments in HGF (r = 0.496,
P = 0.012) (Fig. 3A) and follistatin (r = 0.436, P = 0.029)
(Fig. 3B) at T10 directly correlated with the dose of
enoxaparin, and with one another (r = 0.500, P = 0.011)
(Fig. 3C). In case of HGF, the dose dependency was still
evident at T180 (r = 0.401, P = 0.047). The increases in
activin A at both T10 (r = −0.702, P < 0.0001) (Fig. 3D)
and T180 (r = −0.816, P < 0.0001) strongly and inversely
correlated with the T0 levels.
Effects of a change from LMWH to UFH
As shown in Table 2, plasma HGF levels in 12 patients
switched to UFH increased by 48% at T0, by 23% at T10,
and by 45% at T180 compared with the prerandomiza-
tion values (Fig. 4A). In contrast, over-dialysis plasma
activin A levels did not change (Fig. 4B). Follistatin de-
creased by 46% at T0, by 30% at T10, and by 36% at T180
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Fig. 1. Relationships between plasma hepa-
tocyte growth factor (HGF) and activin A
or follistatin levels in hemodialysis patients
(HD) (A) and healthy subjects (B). Blood
was obtained predialysis from the arteriove-
nous fistula in the patients, and by venepunc-
ture in the controls. The correlations remained
significant after exclusion of the outliers:
two patients with highest baseline HGF (A)
r = 0.437, P = 0.037, and one healthy subject
with follistatin of 2519 pg/mL (B) r = 0.643,
P = 0.005.
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Fig. 2. Case profiles of plasma hepatocyte
growth factor (HGF) (A), activin A (B),
and follistatin (C) levels during enoxaparin-
anticoagulated hemodialysis (HD). Blood
was obtained at the start (before enoxaparin
administration) and at 10 and 180 minutes of
the hemodialysis session. The cytokines were
markedly increased over-dialysis (Wilcoxon
P < 0.0001) except of plasma follistatin, which
returned to baseline at 180 minutes.
(Fig. 4C). The increase in HGF at T0 did not correlate
with the respective fall in follistatin (P = 0.276). Plasma
follistatin levels at T0 in the UFH-anticoagulated patients
were still higher than in healthy controls (P = 0.022).
In the 11 patients who completed the LMWH arm of
the study, the cytokines remained unchanged (Table 2).
Since baseline HGF levels in these subjects were
marginally higher at randomization compared to those
in the 12 patients assigned to UFH (Table 2), additional
analyses were performed. After adjustment for the above
baseline HGF values, the percentage increments in over-
dialysis HGF in the patients switched to UFH remained
statistically different compared with the unchanged cy-
tokine in the LMWH subjects (all P < 0.05). The groups
did not differ with regard to baseline concentrations
of the other factors studied, demographic, clinical, or
laboratory characteristics (data not shown). No bleed-
ing, thrombotic, or infectious complications occurred
during the follow-up. Predialysis leukocytes, hematocrit,
platelets, C-reactive protein, fibrinogen, albumin, liver
enzymes, delivered dialysis dose, ultrafiltration, and dry
body weight did not change in either group (data not
shown). None of the patients required adjustment of the
heparin doses, hemodialysis prescriptions or pharmaco-
logic treatment.
HGF/activin A/follistatin during UFH hemodialysis
The over-dialysis response profiles of the growth fac-
tors under UFH were qualitatively similar to those un-
der LMWH (Table 2). Plasma HGF levels increased by
a mean of 1182% at T10, and by a mean of 515% at T180;
activin A by a median of 168% and 70%, respectively;
follistatin by 54% at T10 (all P< 0.0001). The percent-
age increase in HGF at T10 under UFH was lower than
the previous one under enoxaparin in the 11 respective
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Fig. 3. Variables influencing intradialytic hepatocyte growth factor (HGF), activin A, and follistatin release. The  symbol denotes the change in
plasma cytokine levels at 10 minutes of hemodialysis compared with baseline (T10 to T0). The associations were significant even after deleting the
single outlier with maximal  HGF (A) r = 0.430, P = 0.036 and  follistatin (B) r = 0.393, P = 0.046 and (C) r = 0.442, P = 0.031 or two patients
with  activin A above 1174% (D) r = −0.617, P = 0.002.
subjects (1182% vs. 1636%, P = 0.028). The other
over-dialytic changes were not significantly different vs.
prerandomization.
By contrast to enoxaparin, the percentage increments
in the markers did not correlate with either total, bolus or
infusion dose of UFH (all P > 0.113). As for LMWH, the
percentage increase in activin A both at T10 (r = −0.937,
P < 0.0001) (Fig. 3E) and T180 (r = −0.853, P = 0.0004)
inversely correlated with the T0 levels.
DISCUSSION
The novel findings of this study are that plasma HGF,
activin A, and follistatin compose a system which is
remarkably altered in maintenance hemodialysis patients
compared with healthy subjects, the growth factors are re-
peatedly activated during hemodialysis procedures lead-
ing to depletion of heparin-releasable stores of activin
A, and that the type and dose of heparin used dur-
ing hemodialysis profoundly influence this pleiotropic
system.
Our results are consistent with the previous reports
of increased blood HGF [10–13] and follistatin [18], and
normal activin A levels [17] in chronic hemodialysis pa-
tients. The associations between the factors were, how-
ever, studied for the first time. We found that plasma
HGF was directly correlated with activin A in hemodial-
ysis patients and, by contrast, with follistatin in healthy
controls. The reason for this discrepancy is not clear.
Hypothetically, it may be due to the nature of an
inflammatory response where activin A is one of the
earliest and strongest but short-lived reactants, while
follistatin increases slowly over hours and inhibits ac-
tivin A through a short-loop feedback mechanism [7].
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Table 2. Over-dialysis plasma hepatocyte growth factor (HGF), activin A, and follistatin levels in patients anticoagulated with enoxaparin or
unfractionated heparin during hemodialysis procedures
Before randomization After 12 weeks
0 minutes 10 minutes 180 minutes 0 minutes 10 minutes 180 minutes
Enoxaparin (N = 12) Unfractionated heparin (N = 12)
HGF ng/mL 1.65 (0.66–5.68) 23.4 (15.4–75.0) 8.27 (3.11–17.0) 2.42 (0.95–13.0)a 28.7 (13.2–85.0)c 13.8 (8.41–36.4)a
Activin A pg/mL 122 ± 55.9 331 ± 110 213 ± 70.1 103 ± 48.7 300 ± 107 223 ± 67.6
Follistatin pg/mL 3117 ± 1170 4342 (2885–8557) 2531 (2114–4247) 1677 (1031–8869)c 3038 (1533–13475)c 1616 (635–4124)b
Enoxaparin (N = 11) Enoxaparin (N = 11)
HGF ng/mL 2.02 (1.10–6.20) 29.6 (15.5–154) 7.83 (2.73–98.3) 2.22 (0.87–5.82) 30.8 (12.9–147) 9.09 (3.89–86.3)
Activin A pg/mL 154 ± 98.0 313 ± 134 167 ± 65.1 136 ± 58.0 287 ± 114 187 ± 66.6
Follistatin pg/mL 3494 ± 1074 5018 ± 1781 3068 (2441–5009) 3121 (1028–8669) 5128 (2118–12123) 3261 ± 1004
Data are shown as mean ± 1 SD and median (range) depending on their normal or skewed distribution, respectively. Differences by Wilcoxon signed-rank test between
patients switched from enoxaparin to unfractionated heparin. Mean ± 1 SD value of baseline HGF was 1.85 ± 1.29 ng/mL in patients randomized to unfractionated
heparin (UFH), and 2.49 ± 1.42 ng/mL in patients assigned to UFH; two-tailed P by Mann-Whitney U test = 0.061.
aP < 0.0005; bP < 0.005; cP < 0.05.
Moreover, intermittent hemodialysis patients are not
only exposed three times a week to an acute inflam-
matory stimulus but also to a high dose of heparin.
As shown in the current study, this repeatedly adminis-
tered heparin profoundly activates and disarranges plas-
matic HGF/activin A/follistatin system in hemodialysis
patients.
To our knowledge, the magnitude of the increments
in the growth factors during LMWH enoxaparin-
anticoagulated hemodialysis sessions cannot be
compared to any other moieties studied in this clinical
setting so far. The early increase in circulating HGF
was, in fact, comparable to that in healthy volunteers in
response to intravenous LMWH [27, 28]. In hemodialysis
patients, plasma HGF levels were also found to increase
more than 20-fold after 15 minutes of the session [11, 16],
and remain elevated postdialysis [10, 11, 16] and even
24 hours later [16]. Unfortunately, the type and dose
of used heparin were either not specified [11, 16] or
the regimen consisted of a fixed bolus dose of UFH
[10]. Although the over-dialytic increase in circulating
HGF may be partially due to activation of mononuclear
cells and fibroblasts [11], this and previous studies [10,
11, 15] prove the causal role of heparin. Namely, the
extent of the over-dialytic HGF release in our patients
was directly associated with the dose of LMWH enoxa-
parin; in another report, it was much more pronounced
during a standard than heparin-free hemodialysis [11];
in healthy subjects, the increase in HGF was directly
associated with the plasma antifactor Xa activity as a
surrogate of heparin concentration [27]. Explanation for
these effects is derived from experimental studies where
heparin was proved to bind and displace HGF from
heparan sulfate proteoglycans on the cell surface and
the extracellular matrix [19], form a complex with the
cytokine, and thus prolong its lifetime in the circulation
[20, 21], and enhance HGF production by influencing
posttranscriptional mechanisms [22, 23]. Notably, this
heparin-released circulating HGF was highly bioactive
[11, 27], and its specific pharmacokinetics was maintained
even during prolonged heparin treatment [27].
The marked increase in circulating activin A and fol-
listatin during heparin-anticoagulated hemodialysis is
reported for the first time. The sole related study showed a
several-fold rise in the cytokines occurring within minutes
after a single intravenous injection of UFH in patients
undergoing cardiovascular procedures, and no change
in the markers under placebo administration [24]. The
mechanisms of the increase in circulating activin A and
follistatin by heparin are their displacement from the cell
surface proteoglycans [29] and the dissolution of the com-
plex [30]. In confirmation, the extent of the early rise
in plasma follistatin in our patients, similarly to that in
HGF, was directly dependent on the dose of enoxaparin.
By contrast, the increments in activin A were strongly
and, unexpectedly, inversely associated with the base-
line levels of the cytokine rather than the heparin dose.
These negative associations were highly significant dur-
ing both LMWH- and UFH-anticoagulated hemodialysis
procedures. From a pharmacokinetic point of view, such
regression pattern indicates exhaustion of the reaction
due to depletion of the heparin-releasable pool of a sub-
stance. Its validity was recently proved for tissue factor
pathway inhibitor, which, similarly to activin A, remains
assembled with heparan sulfate glycosaminoglycans.
Depletion of this coagulation inhibitor during repeated
heparin administration attenuates the anticoagulant ef-
fect of the therapy [31]. Thus, our current findings indicate
that three times a week administration of enoxaparin or
UFH in maintenance hemodialysis patients induces de-
pletion of heparin-releasable stores of activin A. Further-
more, the normal predialysis concentrations of activin A,
together with its increased inhibitor follistatin, suggest
that the biologic effects of activin A are suppressed in
these patients. The consequences of this event are difficult
to predict since the systemic effects of activin A are not
yet fully understood. Generally, the cytokine inhibits pro-
liferation and differentiation of various cell types, induces
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Fig. 4. Case profiles of over-dialysis plasma hepatocyte growth factor
(HGF) (A), activin A (B), and follistatin (C) levels in patients switched
from enoxaparin to unfractionated heparin (UFH) anticoagulation.
HGF was increased, activin A was unchanged and follistatin was de-
creased at each time point while on UFH (Table 2). The increments
in HGF were significant even after deleting the patient with HGF of
85.0 ng/mL at 10 minutes of the UFH procedure (A). Exclusion of the
subject with 10 minutes activin A of 577 pg/mL while on UFH (B) did
not change the results.
their apoptosis, and prevents carcinogenesis [5]. Some
of these effects are of particular importance in chronic
hemodialysis patients who commonly present with car-
diovascular disease, chronic inflammation, viral hepatitis,
anemia, impaired immunologic function, and osteodys-
trophy. Notably, bioactive activin A was detected in the
atherosclerotic plaque, inhibited propagation of vascular
endothelial cells, stimulated proliferation of smooth mus-
cle cells, and enhanced differentiation of monocytes into
macrophages [6]. All these actions may promote athero-
genesis and arteriosclerosis. On the other hand, the cy-
tokine was also reported to inhibit foam cell formation
[32] and stabilize the atherosclerotic plaque [33]. The fact
that activin A antagonizes some regenerative actions of
HGF in the kidney and lung [3, 4] suggests, however,
that its depletion may augment the protective effects of
HGF on the cardiovascular system [2]. The role of ac-
tivin A in inflammation is not fully elucidated either;
it seems to be proinflammatory in acute episodes and
anti-inflammatory in a chronic condition [7]. By contrast,
induction of apoptosis in hepatocytes by activin A is well-
established [5, 34]. The liver protection yielded by the
simultaneous inhibition of activin A and up-regulation
of HGF by heparin is thus more explicit. The depletion
of activin A may, however, exacerbate uremic anemia
since the cytokine enhances proliferation and matura-
tion of erythroid progenitors [8]. This effect is likely to
be counterbalanced by the concomitant enhancement of
the erythropoiesis-stimulating HGF [1, 2, 12, 15]. The sup-
pression of activin A may also improve generation and
function of B lymphocytes [8]. On the other hand, it may
harmfully promote heparin-induced osteoporosis since
activin A is a potent bone-healing agent [9]. The issue
that activin A depletion may propagate carcinogenesis
is worrisome [5], especially in view of HGF being also
implicated in this process [1, 2]. Taken together, a novel
and attractive hypothesis emerges that heparin used dur-
ing hemodialysis procedures is not only a mere anticoag-
ulant but also an agent that modulates the course of the
most common diseases in this population.
The results of our prospective controlled study employ-
ing traditional regimens of LMWH and UFH [25, 26] are
in line with intravenous UFH producing higher HGF lev-
els than intravenous LMWH in healthy subjects [27, 28].
The difference may be explained by a larger molecular
size and degree of sulphation of UFH accounting for its
greater binding to both endothelial cells [31] and HGF
molecules [19], and by a lower clearance of circulating
HGF/UFH complexes compared to those with LMWH
[20, 21]. The consequences of HGF up-regulation
under UFH anticoagulation may be important because
circulating HGF is a principal mediator of the angiogenic
[35] and intriguing liver-regenerative effects of heparin
[23, 36]. Interestingly, endogenous heparin derived from
degranulating mast cells in the course of thrombosis also
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stimulates the release of HGF [37], which may then be
used for neoangiogenesis and repair of injured blood
vessels. The clinical significance of circulating HGF mea-
sured after heparin administration was recently estab-
lished by the CAPTURE Study [38]. The cytokine was a
direct and independent predictor of improved long-term
survival in the general population patients with previ-
ous acute coronary syndromes, likely as a result of en-
hanced formation of collateral blood vessels. The results
are in contrast to those in chronic hemodialysis patients
where a high HGF was a negative predictor of survival
[12]. The discrepancy may, however, represent another
example of “reverse epidemiology” of cardiovascular
risks in the hemodialysis population [39], where an
increased HGF reflects the augmented reparative re-
sponse in the most diseased subjects [12–16]. The present
increase in plasma HGF after conversion from LMWH to
UFH may be partially counteracted by the fall in plasma
follistatin. The reason for this behavior of follistatin is
currently not known. These and other under-appreciated
effects of UFH and LMWH on numerous pleiotropic
heparin-binding growth factors [40] deserve further
detailed studies in maintenance hemodialysis patients.
The issue is of special significance because these subjects
are exposed to heparin for years and often for a lifetime.
CONCLUSION
Heparin used for blood anticoagulation during
hemodialysis procedures is an important modulator of
the newly described system of pluripotent growth factors
such as HGF, activin A, and follistatin. Type and dose of
this heparin may have a profound impact on vital body
functions and progression of critical diseases in chronic
hemodialysis patients.
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